Table of Content

1. Overview of Microbiome
  1.1 Introduction to Microbiome
  1.2 History & Evolution of Microbiome

2. Role of Microbiome in Human Body

3. Microbiome: Various Forms
  3.1 Gut Microbiome
  3.2 Lung Microbiome
  3.3 Skin Microbiome
  3.4 Microbiome in Other Parts of the Body

4. Mechanism of Microbiome Activity
  4.1 Nature of Immune Response
    4.1.1 Immunosuppressive Activity
    4.1.2 Immunostimulatory Activity
  4.2 Messengers Involves in Microbiome Mechanism
    4.2.1 MAMPs/PAMPs
    4.2.2 Microbial Metabolites As Messengers
    4.2.3 Host Cytokines As Messengers
    4.2.4 Immune Cells As Messengers

5. Technological Requirement for Microbiota
  5.1 Technologies Used
    5.1.1 iChip
    5.1.2 Simulator of the Human Intestinal Microbial Ecosystem (SHIME)
    5.1.3 Gut-on-a-Chip System
    5.1.4 Colonic Stem Cell Construction
  5.2 Harnessing & Engineering the Microbiome
    5.2.1 Additive Approaches
    5.2.2 Subtractive Approaches
 

6. Need for Microbiome Immunology

7. Therapeutic Applications of Microbiome Immunology
  7.1 Microbiome Therapy
  7.2 Precision Medicine
  7.3 Drug discovery
  7.4 Biomarkers & Therapy Optimization

8. Human Microbiota in Infectious Diseases
  8.1 Infection with Clostridium Difficile
  8.2 Infection with Helicobacter Pylori
  8.3 Bacterial Vaginosis
  8.4 Infection with HIV

9. The Human Microbiota & Liver Diseases
  9.1 Non-Alcoholic Fatty Liver Disease (NAFLD)
  9.2 Alcoholic Liver Diseases (ALD)
  9.3 Liver Fibrosis & Cirrhosis

10. The Human Microbiota & Metabolic Disorders
  10.1 Obesity
  10.2 Type 2 Diabetes

11. The Human Microbiota & Other Diseases
  11.1 Microbiota & Allergic Diseases
  11.2 Microbiota & Psychiatric Diseases

12. Microbiome in Immuno Oncology
  12.1 Role of Microbiome in Immuno Oncology
  12.2 Microbiome Mechanism in Oncogenesis & Tumor Suppression
 

13. Microbiome Application by Cancer Types
  13.1 Gastric Cancer
  13.2 Colorectal Cancer
  13.3 Esophageal Cancer
  13.4 Hepatocellular Carcinoma
  13.5 Melanoma
  13.6 Solid Tumors

14. Industrial Approaches of Microbiome Therapy in Oncology
  14.1 Bacterial Approaches
    14.1.1 Fecal Microbiota Transplantation (FMT)
    14.1.2 Synthetic Bacteria
    14.1.3 Microbial Culture
  14.2 Microbiome as Vaccine
  14.3 Microbiome as Small Molecules
  14.4 Microbiome Therapy using Phage Virus

15. Global Human Microbiome Market Analysis
  15.1 Overview
  15.2 Human Microbiome Market Segmentation
    15.2.1 Regional Segmentation
    15.2.2 Disease Based Segmentation
    15.2.3 Segmentation by Application

16. Clinical Pipeline of Microbiome Based Therapy
  16.1 Microbiome Modulators in Clinical Trial
  16.2 Cancer Related Clinical Trials
    16.2.1 Preclinical & Discovery Phase
    16.2.2 Active Clinical Trials
  16.3 Clinical Trial Related To FMT
    16.3.1 Clinical Trial for Recurrent C. difficile
    16.3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)
    16.3.3 Other FMT Related Clinical Trials
 

17. Global Microbiome Modulators Clinical Pipeline By Company, Indication & Phase
  17.1 Research
  17.2 Preclinical
  17.3 Clinical
  17.4 Phase-I
  17.5 Phase-I/II
  17.6 Phase-II
  17.7 Phase-II/III
  17.8 Phase-III

18. Marketed Microbiome Modulators Clinical Insight
  18.1 Sodium Oligomannurarate - Shanghai Green Valley Pharmaceutical
  18.2 Miya-BM

19. Global Microbiome Immunology Therapeutics Market Growth Drivers

20. Microbiome Technology - Investments, Acquisitions & Collaborations by Leading Microbiome Companies 

21. Blockades in the Microbiome Immunology Market
  21.1 Stable Engraftment
  21.2 Development of Clinically Relevant Sensors
  21.3 Robustness and Evolutionary Stability of Genetic Circuits
  21.4 Regulation, Safety and Biocontainment

22. Global  Microbiome Immunology Market Future Panorama  
 

23. Competitive Landscape
  23.1 4D Pharma
  23.2 AbbVie
  23.3 AstraZeneca plc
  23.4 Biocodex
  23.5 Bristol Mayer Squibb
  23.6 Corebiome/Diversigen
  23.7 Elogi Bioscience
  23.8 Enterome
  23.9 Ferring Pharmaceuticals
  23.10 Finch Therapeutics
  23.11 Maat Pharma
  23.12 Merck
  23.13 Microbiome Therapeutics
  23.14 Novartis
  23.15 OpenBiome
  23.16 Pfizer
  23.17 Rebiotix
  23.18 Second Genome
  23.19 Seres Therapeutics
  23.20 Symberix
  23.21 Takeda Pharmaceuticals
  23.22 Vedanta Bioscience